文献速递血管炎

静脉注射免疫球蛋白治疗ANCA相关性血管炎的疗效:一项荟萃分析

The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该系统综述与荟萃分析纳入9项研究,评估IVIG对活动性ANCA相关性血管炎(AAV)患者的疗效。结果显示,IVIG治疗后6个月内BVAS、ANCA和CRP均显著下降;亚组分析显示未调整免疫治疗人群中,IVIG治疗后半个月内BVAS和CRP即显著下降。结论认为IVIG与活动性AAV疾病活动度及相关生物标志物的快速改善相关。

要点

  • IVIG治疗后6个月内BVAS、ANCA和CRP均显著下降。
  • 未调整免疫治疗人群中,IVIG后半个月内BVAS和CRP即显著下降。
  • IVIG与活动性AAV疾病活动度及相关生物标志物的快速改善相关。

核心结论

  • IVIG与活动性AAV患者疾病活动度及相关生物标志物的快速改善相关。

研究设计与样本

  • 按照PRISMA指南进行的系统综述与荟萃分析,检索PubMed和Google Scholar,共识别220项研究,最终纳入9项符合标准的研究。
  • 纳入研究均为活动性AAV患者接受IVIG作为免疫调节治疗,收集治疗前后临床数据。
  • 采用随机效应模型计算标准化均数差(SMD)及95%CI。

主要发现

  • IVIG治疗后6个月内BVAS显著下降(SMD -1.7;95% CI [-2.66, -0.73];P = 0.0006)。
  • IVIG治疗后6个月内ANCA显著下降(SMD -0.72;95% CI [-1.13, -0.31];P = 0.0006)。
  • IVIG治疗后6个月内CRP显著下降(SMD -0.92;95% CI [-1.49, -0.35];P = 0.002)。
  • 未调整免疫治疗人群亚组中,IVIG治疗后半个月内BVAS下降(SMD -1.39;95% CI [-2.31, -0.48];P = 0.003)。
  • 未调整免疫治疗人群亚组中,IVIG治疗后半个月内CRP下降(SMD -0.56;95% CI [-0.93, -0.19];P = 0.002)。

临床怎么用

  • 对于活动性AAV患者,IVIG可作为免疫调节治疗以快速改善疾病活动度及相关生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The therapeutic effects of IVIG in patients with ANCA-associated vasculitis (AAV) have not been established so far. This study aims to estimate the effects of IVIG on AAV by conducting a systematic review and meta-analysis. METHODS: A comprehensive systematic review was conducted in accordance with the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews And Meta-analyses). PubMed and Google Scholar were used to search for original studies on AAV and collect clinical data before and after IVIG treatment. A meta-analysis of each clinical parameter was performed, and standardized mean difference (SMD) and 95% CI were calculated using the random effects model. RESULTS: A total of 220 studies were identified, and nine met the selection criteria for the meta-analysis. IVIG was administered to active AAV patients as an immunomodulatory therapy in the nine studies selected. Significant reductions in BVAS (SMD -1.7; 95% CI [-2.66, -0.73]; P = 0.0006), ANCA (SMD -0.72; 95% CI [-1.13, -0.31]; P = 0.0006) and CRP (SMD -0.92; 95% CI [-1.49, -0.35]; P = 0.002) were noted within 6 months after administration of IVIG. Subgroup analysis in the unmodified immunotherapy population showed reductions in BVAS (SMD -1.39; 95% CI [-2.31, -0.48]; P = 0.003) and CRP (SMD -0.56; 95% CI [-0.93, -0.19]; P = 0.002) within half a month after IVIG treatment. CONCLUSION: IVIG was associated with rapid improvements in disease activity and the related biomarkers in patients with active AAV.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shimizu T, Morita T, Kumanogoh A, et al. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2020. PMID: 31377800. doi:10.1093/rheumatology/kez311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。